ArticleClinical pharmacology and therapeutics2016
The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.
Article in Clinical pharmacology and therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 72 citations in OpenAlex.
- Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects.Pain research & management · 2018Trial
- Oral Human Abuse Potential of Oxycodone DETERxJournal of clinical pharmacology · 2017Trial
- From addiction to aggression: The spillover effects of opioid policies on intimate partner violence.Journal of health economics · 2025Article
- Abuse-deterrent formulations and opioid-related harms in North Carolina, 2010-2018.American journal of epidemiology · 2025Article
- Multidimensional opioid abuse deterrence using a nanoparticle-polymer hybrid formulation.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- Review of Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access.Journal of pain research · 2024Review
- The effects of opioid policy changes on transitions from prescription opioids to heroin, fentanyl and injection drug use: a qualitative analysis.Substance abuse treatment, prevention, and policy · 2022Article
- Abuse-deterrent extended-release oxycodone and risk of opioid-related harm.Addiction (Abingdon, England) · 2021Article
- Non-medical Use of Prescription Stimulants Among College Students: Non-oral Routes of Administration, Risk Factors, Motivations, and Pathways.Frontiers in psychiatry · 2021Article
- Strengths and weaknesses of existing data sources to support research to address the opioids crisis.Preventive medicine reports · 2020Review
- Healthcare Resource Use and Cost: The Impact of Adopting an Abuse-Deterrent Formulation of Extended Release Morphine.ClinicoEconomics and outcomes research : CEOR · 2020Article
- Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting.Addiction (Abingdon, England) · 2019Article
- Efficacy And Safety Of Controlled-Release Oxycodone For The Management Of Moderate-To-Severe Chronic Non-Cancer Pain In Japanese Patients: Results From An Open-Label Study.Journal of pain research · 2019Article
- Relative Abuse of Crush-Resistant Prescription Opioid Tablets via Alternative Oral Modes of Administration.Pain medicine (Malden, Mass.) · 2018Article
- Determining Abuse Deterrence Performance of Poly (ethylene oxide) Using a Factorial Design.Advanced pharmaceutical bulletin · 2018Article
- Comment on Mayock SP, Saim S, Fleming AB. In Vitro Drug Release After Crushing: Evaluation of XtampzaClinical drug investigation · 2018Article
- Are Prescription Opioids Driving the Opioid Crisis? Assumptions vs Facts.Pain medicine (Malden, Mass.) · 2018Review
- Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics.Anesthesia and analgesia · 2017Review
- Breaking barriers to novel analgesic drug development.Nature reviews. Drug discovery · 2017Review
- In response to Gudin et al. - Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.Pain medicine (Malden, Mass.) · 2017Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An extended-release opioid analgesic (OxyContin, OC) was reformulated with abuse-deterrent properties to deter abuse. This report examines changes in abuse through oral and nonoral routes, doctor-shopping, and fatalities in 10 studies 3.5 years after reformulation. Changes in OC abuse from 1 year before to 3 years after OC reformulation were calculated, adjusted for prescription changes. Abuse of OC decreased 48% in national poison center surveillance systems, decreased 32% in a national drug treatment system, and decreased 27% among individuals prescribed OC in claims databases. Doctor-shopping for OC decreased 50%. Overdose fatalities reported to the manufacturer decreased 65%. Abuse of other opioids without abuse-deterrent properties decreased 2 years later than OC and with less magnitude, suggesting OC decreases were not due to broader opioid interventions. Consistent with the formulation, decreases were larger for nonoral than oral abuse. Abuse-deterrent opioids may mitigate abuse and overdose risks among chronic pain patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.